AACR Annual Meeting 2021 – Poster 1080
Understanding the clinical resistance to kinase inhibitors

Comparative cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020
Download poster (Pdf)

Discovery of Precision Oncology Drugs

NTRC provides in vitro drug discovery services focused on Precision Medicine. We help you to find the informed route to the clinic. Information can be found at www.oncolines.com

Understanding the clinical resistance to kinase inhibitors

The work presented in this poster elucidates the resistance mechanisms that cancer cell lines develop in vitro to the FGFR kinase inhibitor erdafitinib. Furthermore, it provides insight into inhibitors that are of potential use for treatment of erdafitinib-resistant cancers.

NTRC ONCOLINES™

Access Cancer Cell Lines, Proliferation Assays and Bioinformatics Analysis to Find Patient Stratification Markers

ONCOLINES

read more
NTRC SYNERGYFINDER™

Apply Combination Studies
to Identify
Novel Synergies

SYNERGYFINDER

read more
NTRC Mechanistic Cell Biology

Use Cell-Based Assays
to Determine
Mechanism of Action

MECHANISTIC CELL BIOLOGY

read more

Information Needed?

Please contact us for more information

+31 412 700501
Send e-mail